For more information, see the NHS hypoglycaemia information page
While improved metabolic stability may reduce the need for frequent in-person visits, it does not eliminate the need for ongoing monitoring
10,33 Similarly, the REWIND trial, in patients with T2D and established CVD or cardiovascular risk factors, reported that dulaglutide significantly reduced the incidence of MACE (primary outcome)
10.3390/cells9030695 22 DixonS
In the trials, different dosage levels are being tested to see how they impact weight loss and other health markers
Prime provides care to millions of people across the country through pharmacy benefit management, specialty and medical drug management, and state government solutions